Latest News
Source:
Date range from
to
Keyword:
NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen
eCancer (EU) - 11/05/2012
NHS patients are refused 'too expensive' prostate cancer drug good enough for Lockerbie terrorist al-Megrahi
Daily Mail (UK) - 11/05/2012
Libyan terrorist al-Megrahi, 60, is taking cabazitaxel and has survived for three years after he was released on compassionate grounds from a Scottish prison after a doctor said he had only three months to live.
Time for another rethink on prostate cancer screening
Cancerworld (EU) - 10/05/2012
The US Preventive Services Task Force (USPSTF) recently issued a recommendation against the use of prostate-specific antigen (PSA) testing for prostate cancer screening.[1] They concluded that “there is moderate or high certainty that [prostate cancer screening] has no net benefit or that the harms outweigh the benefits.” In this article, we review the USPSTF report and make three simple points. First, the USPSTF report is riddled with errors, so much so that we would be sympathetic to accusations that the task force was biased.
DNA test for prostate cancer relapse
Behind the Headlines (NHS, UK) - 08/05/2012
“A blood test for men with prostate cancer could detect if the illness is likely to be life-threatening,” the Daily Mail has reported. In some cases prostate cancer can be benign, but in others it can be life-threatening and require treatment such as surgery or chemotherapy.
DNA test for prostate cancer relapse
NHS Choices (UK) - 08/05/2012
“A blood test for men with prostate cancer could detect if the illness is likely to be life-threatening,” the Daily Mail has reported. In some cases prostate cancer can be benign, but in others it can be life-threatening and require treatment such as surgery or chemotherapy.
Genetic variation 'predicts behaviour of prostate cancer'
Cancer Research UK - 08/05/2012
Measuring a type of genetic variation in the blood of men with prostate cancer could help predict how their disease will develop, according to US research.
Younger And At-Risk Men Benefit From PSA Screening To Detect Prostate Cancer
Medical News Today (UK) - 08/05/2012
Screening younger men and men at risk of prostate cancer can be beneficial in reducing metastatic cancer and deaths and should not be abandoned, states an article published in CMAJ (Canadian Medical Association Journal). The United States Preventive Services Task Force, which last issued prostate screening guidelines in 2008, recently issued a draft recommendation against prostate-specific antigen (PSA) screening for men of all ages.
In Prostate Cancer, Genetic Abnormalities In Benign Or Malignant Tissues Predict Relapse
Medical News Today (UK) - 08/05/2012
While active monitoring of serum prostate specific antigen (PSA) levels in men over 50 has greatly improved early detection of prostate cancer, prediction of clinical outcomes after diagnosis remains a major challenge...
PSA screening to detect prostate cancer can be beneficial to younger and at-risk men
eCancer (EU) - 08/05/2012
Ancient Remedy Slows Prostate Tumor Cell Proliferation
Medical News Today (UK) - 08/05/2012
An over-the-counter natural remedy derived from honeybee hives arrests the growth of prostate cancer cells and tumors in mice, according to a new paper from researchers at the University of Chicago Medicine. Caffeic acid phenethyl ester, or CAPE, is a compound isolated from honeybee hive propolis, the resin used by bees to patch up holes in hives. Propolis has been used for centuries as a natural remedy for conditions ranging from sore throats and allergies to burns and cancer.
New blood test could provide hint of a prostate cancer relapse
Daily Mail (UK) - 07/05/2012
Researchers from the University of Pittsburgh claim that testing blood for a genetic abnormality - called the CNV - determines how quickly the cancer will spread.
Researchers separate low and high-PSA prostate cancer cells
News Medical (Australia) - 07/05/2012
Prostate cancer cells that defy treatment and display heightened tumor-generating capacity can be identified by levels of prostate specific antigen (PSA) expressed in the tumor cells, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the May 3 edition of Cell Stem Cell.
Prostate Cancer Stem Cells Identified Among Low-PSA Cells
Medical News Today (UK) - 07/05/2012
Prostate cancer cells that defy treatment and display heightened tumor-generating capacity can be identified by levels of prostate specific antigen (PSA) expressed in the tumor cells, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in Cell Stem Cell. "Using a new technique, we were able for the first time to separate low-PSA and high-PSA prostate cancer cells...
Scientists identify prostate cancer stem cells among low-PSA cells
Science Daily (US) - 04/05/2012
Prostate cancer cells that defy treatment and display heightened tumor-generating capacity can be identified by levels of prostate specific antigen (PSA) expressed in the tumor cells, scientists have found.
Prostate cancer on the rise but deaths remain steady
totalhealth - 04/05/2012
Following the implementation of a new screeningA way to identify people who may have a certain condition, among a group of people who may or may not seem to test for prostateA gland that surrounds the urethra near the bladder.
Beehive extract shows potential as prostate cancer treatment
Science Daily (US) - 04/05/2012
An over-the-counter natural remedy derived from honeybee hives arrests the growth of prostate cancer cells and tumors in mice, according to a new article. Researchers combined traditional cancer research methods with cutting-edge proteomics to find that CAPE arrests early-stage prostate cancer by shutting down the tumor cells' system for detecting sources of nutrition.
Prostate cases treble in 20 years: But as more are diagnosed with cancer, fewer men die
Daily Mail (UK) - 04/05/2012
The prostate cancer diagnosis rate has reached a record high. More than 40,000 men were found to have the disease in 2009, up from 14,000 two decades earlier. But experts say a better test is needed to identify cases that need treating.
